We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

103 hedge funds and large institutions have $677M invested in BioCryst Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 38 increasing their positions, 15 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 15

152% more call options, than puts

Call options by funds: $11.8M | Put options by funds: $4.71M

94% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 17

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

47% more capital invested

Capital invested by funds: $461M → $677M (+$216M)

17% more funds holding

Funds holding: 88 → 103 (+15)

Holders
103
Holders Change
+15
Holders Change %
+17.05%
% of All Funds
2.96%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
33
Increased
38
Reduced
15
Closed
17
Calls
$11.8M
Puts
$4.71M
Net Calls
+$7.14M
Net Calls Change
+$3.88M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$48.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$17M
3
BFA
BlackRock Fund Advisors
California
+$16.2M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$12.9M
5
BIT
BlackRock Institutional Trust
California
+$8.42M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$16.7M
2
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
-$12.3M
3
RCM
RA Capital Management
Massachusetts
-$11.2M
4
DM
Deerfield Management
New York
-$9.61M
5
Millennium Management
Millennium Management
New York
-$4.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
26
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$2.03M -$3.68M -378,700 -72%
Millennium Management
27
Millennium Management
New York
$1.89M -$4.29M -441,454 -75%
California Public Employees Retirement System
28
California Public Employees Retirement System
California
$1.84M – – –
BG
29
BlackRock Group
United Kingdom
$1.79M +$1.16M +119,443 +575%
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$1.63M +$1.24M +127,900 New
AQR Capital Management
31
AQR Capital Management
Connecticut
$1.44M +$10.7K +1,100 +1%
SIM
32
Spark Investment Management
New York
$1.43M +$572K +58,800 +111%
ARTA
33
A.R.T. Advisors
New York
$1.38M +$74.2K +7,625 +8%
Jane Street
34
Jane Street
New York
$1.36M -$717K -73,659 -41%
AllianceBernstein
35
AllianceBernstein
Tennessee
$1.35M +$1.03M +105,800 New
USAA
36
United Services Automobile Association
Texas
$1.32M +$10.7K +1,100 +1%
PP
37
PDT Partners
New York
$1.28M +$589K +60,540 +151%
TA
38
Teachers Advisors
New York
$1.25M +$955K +98,183 New
Citadel Advisors
39
Citadel Advisors
Florida
$1.22M +$829K +85,247 +788%
Bank of America
40
Bank of America
North Carolina
$1.19M +$86.4K +8,879 +11%
FSA
41
Franklin Street Advisors
North Carolina
$1.19M – – –
Commonwealth Equity Services
42
Commonwealth Equity Services
Massachusetts
$1.15M +$459K +47,200 +109%
EI
43
EAM Investors
California
$1.09M -$280K -28,827 -25%
HCM
44
Highbridge Capital Management
New York
$1.05M +$803K +82,546 New
SM
45
Sabby Management
Florida
$994K +$759K +77,987 New
ProShare Advisors
46
ProShare Advisors
Maryland
$977K +$305K +31,373 +69%
Swiss National Bank
47
Swiss National Bank
Switzerland
$954K +$191K +19,600 +36%
U
48
UBS
Switzerland
$876K -$937K -96,291 -58%
RFC
49
Russell Frank Company
Washington
$872K -$18.6K -1,910 -3%
BlackRock
50
BlackRock
New York
$866K +$661K +67,903 +485,021%
1
2
3 4 5

BCRX Hedge Fund Activity: Q2 2014 in Review

103 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2014, worth a combined $677M — up 47% from $461M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new BCRX positions and 17 closed out — a net gain of 16 holders — while 38 added to existing stakes and 15 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $48.9M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $16.7M sold.

  • 103 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2014, up from 88 in Q1 2014.
  • Funds reported $677M of BioCryst Pharmaceuticals stock for Q2 2014, up 47% quarter-over-quarter.
  • 33 funds opened new BioCryst Pharmaceuticals positions in Q2 2014 and 17 closed out, a net change of +16 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q2 2014 was Baker Bros. Advisors, an estimated $48.9M added.
  • The largest BioCryst Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $16.7M sold.

Based on aggregated 13F filings for Q2 2014.